Biological Psychiatry

Journal

Publication Venue For

  • Central Amygdala Discovery Efforts in Primates Reveals New Clues on Anxious Temperament.  88:e35-e36. 2020
  • Reciprocal Copy Number Variations at 22q11.2 Produce Distinct and Convergent Neurobehavioral Impairments Relevant for Schizophrenia and Autism Spectrum Disorder.  88:260-272. 2020
  • The Genetics of the Mood Disorder Spectrum: Genome-wide Association Analyses of More Than 185,000 Cases and 439,000 Controls.  88:169-184. 2020
  • The SETD6 Methyltransferase Plays an Essential Role in Hippocampus-Dependent Memory Formation.  87:577-587. 2020
  • Targeted Treatment of Individuals With Psychosis Carrying a Copy Number Variant Containing a Genomic Triplication of the Glycine Decarboxylase Gene.  86:523-535. 2019
  • Partial Loss of USP9X Function Leads to a Male Neurodevelopmental and Behavioral Disorder Converging on Transforming Growth Factor β Signaling 2019
  • AMPA Receptor Activation–Independent Antidepressant Actions of Ketamine Metabolite (S)-Norketamine.  84:591-600. 2018
  • Connective Tissue Growth Factor Is a Novel Prodepressant.  84:555-562. 2018
  • Volume of the Human Hippocampus and Clinical Response Following Electroconvulsive Therapy.  84:574-581. 2018
  • Reply to: It Is Time to Look for New Treatments for Posttraumatic Stress Disorder: Can Sympathetic System Modulation Be an Answer?.  84:e19-e20. 2018
  • Genetic Overlap Between Attention-Deficit/Hyperactivity Disorder and Bipolar Disorder: Evidence From Genome-wide Association Study Meta-analysis.  82:634-641. 2017
  • It Is Time to Address the Crisis in the Pharmacotherapy of Posttraumatic Stress Disorder: A Consensus Statement of the PTSD Psychopharmacology Working Group.  82:e51-e59. 2017
  • Imaging biomarkers associated with cognitive decline: a review..  77:685-692. 2015
  • Coordinated messenger RNA/microRNA changes in fibroblasts of patients with major depression.  77:256-265. 2015
  • Genome-wide studies of verbal declarative memory in nondemented older people: The Cohorts for Heart and Aging Research in Genomic Epidemiology Consortium.  77:749-763. 2015
  • Meta-analysis of face processing event-related potentials in schizophrenia.  77:116-126. 2015
  • Glycogen synthase kinase-3 inhibitors reverse deficits in long-term potentiation and cognition in fragile X mice.  75:198-206. 2014
  • Sirtuin activity in dentate gyrus contributes to chronic stress-induced behavior and extracellular signal-regulated protein Kinases 1 and 2 cascade changes in the hippocampus.  74:927-935. 2013
  • Social isolation exacerbates schizophrenia-like phenotypes via oxidative stress in cortical interneurons.  73:1024-1034. 2013
  • Inflammatory T helper 17 cells promote depression-like behavior in mice.  73:622-630. 2013
  • Magnetic transfer contrast accurately localizes substantia nigra confirmed by histology.  73:289-294. 2013
  • Abnormalities of the Duo/Ras-related C3 botulinum toxin substrate 1/p21-activated kinase 1 pathway drive myosin light chain phosphorylation in frontal cortex in schizophrenia.  71:906-914. 2012
  • Phasic nucleus accumbens dopamine encodes risk-based decision-making behavior.  71:199-205. 2012
  • Glutamatergic gene expression is specifically reduced in thalamocortical projecting relay neurons in schizophrenia.  70:646-654. 2011
  • Cocaine cues drive opposing context-dependent shifts in reward processing and emotional state.  69:1067-1074. 2011
  • Novel approaches to the study of postmortem brain in psychiatric illness: Old limitations and new challenges.  69:127-133. 2011
  • Attention-deficit/hyperactivity phenotype in mice lacking the cyclin-dependent kinase 5 cofactor p35.  68:1163-1171. 2010
  • Assessments of function and biochemistry of the anterior cingulate cortex in schizophrenia.  68:625-633. 2010
  • Phasic nucleus accumbens dopamine release encodes effort- and delay-related costs.  68:306-309. 2010
  • Modulation in Activation and Expression of Phosphatase and Tensin Homolog on Chromosome Ten, Akt1, and 3-Phosphoinositide-Dependent Kinase 1: Further Evidence Demonstrating Altered Phosphoinositide 3-Kinase Signaling in Postmortem Brain of Suicide Subjects.  67:1017-1025. 2010
  • Basolateral Amygdala Modulates Terminal Dopamine Release in the Nucleus Accumbens and Conditioned Responding.  67:737-744. 2010
  • Lasting Epigenetic Influence of Early-Life Adversity on the BDNF Gene.  65:760-769. 2009
  • Neurotrophin Receptor Activation and Expression in Human Postmortem Brain: Effect of Suicide.  65:319-328. 2009
  • Saliva Estriol Levels in Women with and Without Prenatal Antidepressant Treatment.  64:533-537. 2008
  • Altered Vesicular Glutamate Transporter Expression in the Anterior Cingulate Cortex in Schizophrenia.  63:766-775. 2008
  • The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the Acute and Continuation Phases.  62:1371-1379. 2007
  • Are Antidepressant Drugs That Combine Serotonergic and Noradrenergic Mechanisms of Action More Effective Than the Selective Serotonin Reuptake Inhibitors in Treating Major Depressive Disorder? A Meta-analysis of Studies of Newer Agents.  62:1217-1227. 2007
  • Tumor Necrosis Factor-α and Its Inducer Inhibit Morphine-Induced Rewarding Effects and Sensitization.  62:658-668. 2007
  • Inhibitory Control in High-Functioning Autism: Decreased Activation and Underconnectivity in Inhibition Networks.  62:198-206. 2007
  • Attention-Deficit/Hyperactivity Disorder and Comorbid Disruptive Behavior Disorders: Evidence of Pleiotropy and New Susceptibility Loci.  61:1329-1339. 2007
  • An Inducer for Glial Cell Line-Derived Neurotrophic Factor and Tumor Necrosis Factor-α Protects Against Methamphetamine-Induced Rewarding Effects and Sensitization.  61:890-901. 2007
  • Lithium Regulates Glycogen Synthase Kinase-3β in Human Peripheral Blood Mononuclear Cells: Implication in the Treatment of Bipolar Disorder.  61:216-222. 2007
  • Polymorphisms in the Regulatory Region of the Human Serotonin 5-HT2A Receptor Gene (HTR2A) Influence Gene Expression.  61:167-173. 2007
  • Schizophrenia-Relevant Behavioral Testing in Rodent Models: A Uniquely Human Disorder?.  59:1198-1207. 2006
  • Diffusion tensor imaging in schizophrenia.  58:921-929. 2005
  • Regarding “Antibiotic Prophylaxis with Azithromycin or Penicillin for Childhood-Onset Neuropsychiatric Disorders”.  58:917-917. 2005
  • Suicide brain is associated with decreased expression of neurotrophins.  58:315-324. 2005
  • Deep brain stimulation for refractory obsessive-compulsive disorder.  57:510-516. 2005
  • Neurochemical markers for schizophrenia, bipolar disorder, and major depression in postmortem brains.  57:252-260. 2005
  • Altered protein kinase A in brain of learned helpless rats: Effects of acute and repeated stress.  56:30-40. 2004
  • Effect of agonal and postmortem factors on gene expression profile: Quality control in microarray analyses of postmortem human brain.  55:346-352. 2004
  • Protein kinase a in postmortem brain of depressed suicide victims: Altered expression of specific regulatory and catalytic subunits.  55:234-243. 2004
  • Metabotropic glutamate receptor mRNA expression in the schizophrenic thalamus.  47:22-28. 2000
  • Effects of left frontal transcranial magnetic stimulation on depressed mood, cognition, and corticomotor threshold.  45:1440-1446. 1999
  • D-fenfluramine challenge in posttraumatic stress disorder.  45:928-930. 1999
  • Protein kinase C in platelets of depressed patients.  44:909-911. 1998
  • Regulated phosphorylation and trafficking of antidepressant-sensitive serotonin transporter proteins.  44:169-178. 1998
  • Antipsychotic properties of the partial dopamine agonist (-)-3-(3- hydroxyphenyl)-N-n-propylpiperidine (preclamol) in schizophrenia.  43:2-11. 1998
  • Eye tracking disorder in schizophrenia is characterized by specific ocular motor defects and is associated with the deficit syndrome.  42:781-796. 1997
  • Antipsychotic regulation of hippocampal dopamine receptor messenger RNA expression.  42:155-164. 1997
  • Effects of cocaine on D3 and D4 receptor expression in the human striatum.  38:263-266. 1995
  • Ventricular enlargement, neuropsychological status, and premorbid function in schizophrenia.  35:517-524. 1994
  • Effects of cocaine on dopamine receptor gene expression: A study in the postmortem human brain.  34:348-355. 1993
  • The effects of antidepressants on the thyroid axis in depression.  33:120-126. 1993
  • Expression of the dopamine D2 receptor gene in brain.  30:985-1007. 1991
  • Dexamethasone suppression test in schizophrenia: Relationship to symptomatology, ventricular enlargement, and outcome.  29:953-964. 1991
  • Basal ganglia mineralization in schizophrenia.  29:296-297. 1991
  • Multiplicity of depressive episodes: Phenomenological and neuroendocrine correlates.  27:1156-1164. 1990
  • γ-melanotropin and β-endorphin after dexamethasone.  25:975-976. 1989
  • Positive and negative symptoms in schizophrenia and the dexamethasone suppression test.  25:788-792. 1989
  • Dexamethasone suppression test status and severity of depression.  24:693-696. 1988
  • Multiple depressive episodes and plasma postdexamethasone cortisol levels.  22:583-592. 1987
  • Postdexamethasone plasma cortisol and β-endorphin levels in depression: Relationship to severity of illness.  22:1137-1150. 1987
  • A negative, double-blind, placebo-controlled, clinical trial of verapamil in chronic schizophrenia.  21:691-694. 1986
  • Quantification of muscle tremor of Huntington's disease patients and their offspring in an early detection study.  14:777-789. 1979
  • Diminution of early environmental control through perinatal and prenatal somatosensory deafferentation.  10:609-626. 1975
  • International Standard Serial Number (issn)

  • 0006-3223
  • Electronic International Standard Serial Number (eissn)

  • 1873-2402